Market News & Trends
Sebia Enters Development Agreement With Sanofi
Sebia recently announced it is entering into an agreement with Sanofi to develop an in vitro diagnostic (IVD) test that mitigates the potential interference caused by……
WPD Pharmaceuticals’ New Discovery for Cancer Targeting Drugs is Granted Patent
WPD Pharmaceuticals recently announced Wake Forest University received a patent from the United States Patent and Trademark Office (USPTO) for patent 105019210 (issued under application…
Oxford BioTherapeutics Initiates Dose-Escalation Portion of Phase I Clinical Trial
Oxford BioTherapeutics Ltd. recently announced the initiation of the dose-escalation portion of its US Phase 1 program for OBT076, a CD205 targeting antibody-drug conjugate (ADC),…
Zai Lab & Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial
Zai Lab Limited and Novocure recently announced the first patient has been enrolled in a Phase 2 pilot clinical trial evaluating the safety and efficacy…
TYME Announces First Patient Dosed in Pivotal Trial
Tyme Technologies, Inc. recently announced the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval…
Bayer Exercises Right to Enter Follow-On Research & Collaboration Option Agreement
Bayer and Atomwise, the leader in artificial intelligence (AI) for drug discovery, recently announced the companies will continue the development of two crop protection programs.…
ArTara Therapeutics Completes Merger Transaction With Proteon Therapeutics
ArTara Therapeutics, Inc. recently announced the completion of the merger with Proteon Therapeutics, Inc.and associated equity financing. The merged company will operate under the name…
Patent Filed for Nitric Oxide Delivery Device That is Comparable to Inhalers
Nu-Med Plus, Inc., a medical device development company, recently announced that a patent has been filed for a nitric oxide delivery device that is designed for…..
New Publication Demonstrates GeneSight Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study
Myriad Genetics, Inc. recently announced that a new analysis of the GUIDED clinical trial using the 6-item Hamilton Depression Rating Scale (HAM-D6) was published online in BMC Psychiatry. The key finding is….
Cytovia Therapeutics & the University of California, San Francisco Enter Partnership to Develop Precision Gene-Edited CAR-NK Cell Therapy
Cytovia Therapeutics and the University of California, San Francisco (UCSF) recently announced they have entered a 3-year research partnership to develop novel precision gene editing…
Acceleron & Fulcrum Therapeutics Announce Pulmonary Research & Discovery Collaboration Agreement
Acceleron Pharma Inc. and Fulcrum Therapeutics, Inc. recently announced they have entered into a collaboration and license agreement to identify small molecules designed to modulate…
WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – recently announced the opening of its large-scale oligonucleotide active pharmaceutical ingredient (API)…
Pfenex Earns $15-Million Development Milestone Under its Development & License Agreement
Pfenex Inc. recently announced it has earned a $15-million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated…
Opiant Pharmaceuticals Announces Development Collaboration With National Center for Advancing Translational Sciences
Opiant Pharmaceuticals, Inc. recently announced it has signed a Letter of Intent with the National Center for Advancing Translational Sciences (NCATS) to collaborate on the…
FDA Approves Intra-Cellular Therapies’ Novel Treatment of Schizophrenia in Adults
Intra-Cellular Therapies, Inc. recently announced that CAPLYTA (lumateperone) has been approved by the US FDA for the treatment of schizophrenia in adults. The company expects…
Celgene Had the Highest R&D Spend in 2018
Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData’s Company Financials database. An analysis…
Catalent Launches New CTSuccess(TM) Service to Guide Sponsors to Smarter Clinical Trial Supply Planning
Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors…
Bioiberica Launches Natural Origin Thyroid
Bioiberica, a world reference in the identification, extraction, and development of animal-derived APIs, recently announced the launch of its natural thyroid active pharmaceutical ingredient (API) for the treatment of…..
Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug
Tetra Bio-Pharma Inc. recently announced it will be requesting a meeting with the US FDA to discuss the drug development program for its Orphan Drug candidate HCC011….
Catalent Partners With Bridge Therapeutics on Formulation, Development & Production of New Opioid Addiction Treatment
Catalent recently announced it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an….
